Helsinn Pharmaceuticals opens office in Shanghai

Swiss oncology specialist Helsinn Pharmaceuticals has announced the expansion of its footprint in China, with the opening of a Shanghai branch.

The company says it anticipates the first Chinese approvals next year, and it plans to continue expanding in China via a commercial arm focused on Shanghai.

Helsinn has regulatory submissions for several of its supportive care products pending with the China FDA.

Chief executive Riccardo Braglia said: “Helsinn has been developing a presence in China over the past five years and we have developed valuable experience, learnings and networks.”